The Characterization and Imaging Behavior of a New Developed Paramagnetic Contrast Agent NMG2[Gd(TTDA-BOM)].
[Gd(TTDA-BOM)]<sup>2-</sup>is a newly developed paramagnetic contrast agent.The ligand,TTDA-BOM,bears a benzyloxymethyl group so that the lipophilicity is increased. The water exchange rate for [Gd(TTDA-BOM)]<sup>2-</sup>is significantly higher than that of [Gd(DTPA)]<sup>2-</sup>and [Gd(BOPTA)]<sup>2-</sup>.In addition, the bound relaxivity of this Gd (III) complex has a remarkably high value with HSA. Therefore,it has potential to be used as a blood pool contrast agent for MRI. The aim of this study is to investigate the characterization and imaging behavior of NMG<inf>2</inf>[Gd(TTDA-BOM)] in normal rat livers and hearts using a 3T high field whole-body MR scanner.The high field MR scanner is expected to have a higher signal to noise ratio. The relaxivities r<inf>1</inf>and r<inf>2</inf>for [Gd(TTDA-BOM)]<sup>2-</sup>at 3T are 5.97 mM<sup>-1</sup>s<sup>-1</sup>and 7.99 mM<sup>-1</sup>s<sup>-1</sup>respectively, which are higher than those for [Gd(DTPA)]<sup>2</sup>(r1=4.64 mM<sup>-1</sup>s<sup>-1</sup>and r<inf>2</inf>= 5.08 mM<sup>-1</sup>s<sup>-1</sup>). The dynamic MRI studies show that there is marked enhancement in livers and hearts right after the bolus injection and the enhancement ratios keep high until two hours. In conclusion, [Gd(TTDA-BOM)]<sup>2-</sup>might have a good potential in both cardiovascular and hepatobiliary applications.